Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
surufatinib + toripalimab + albumin-bound paclitaxel + cisplatin
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This treatment regimen is a multi-modal combination therapy being evaluated for the treatment of unresectable locally advanced esophageal squamous cell carcinoma (ESCC). It consists of **surufatinib**, a small molecule angio-immuno kinase inhibitor that targets VEGFR1/2/3, FGFR1, and CSF1R; **toripalimab**, a monoclonal antibody that acts as a PD-1 checkpoint inhibitor; and a chemotherapy backbone of **albumin-bound paclitaxel** and **cisplatin**. The regimen is typically administered in a neoadjuvant setting, often followed by or concurrent with definitive thoracic intensity-modulated radiotherapy (IMRT). Surufatinib's mechanism of action involves inhibiting tumor angiogenesis and modulating the tumor immune microenvironment by reducing tumor-associated macrophages, which is intended to synergize with the T-cell activation provided by toripalimab and the cytotoxic effects of chemotherapy to improve resectability and overall prognosis.
- Brand names
- SulandaTuoyiAbraxane
- Other names
- neoadjuvant immunochemotherapy-Sun Yat-sen University-esophageal squamous cell carcinomaSurufatinib in combination with neoadjuvant chemo-immunotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)CSF1R (Macrophage colony-stimulating factor receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)TUBB (Tubulin (alpha and beta subunits))FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on surufatinib + toripalimab + albumin-bound paclitaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on surufatinib + toripalimab + albumin-bound paclitaxel + cisplatin.